LUIS ALDÁMIZ-ECHEVARRÍA AZUARA-rekin lankidetzan egindako argitalpenak (60)

2020

  1. Cribado selectivo de la hipofosfatasia en la población pediátrica del País Vasco

    Boletín de la Sociedad Vasco-Navarra de pediatría = Euskal Herriko Pediatria Elkartearen aldizkaria, Núm. 121, pp. 14-17

  2. Non-alcoholic fatty liver in hereditary fructose intolerance

    Clinical Nutrition, Vol. 39, Núm. 2, pp. 455-459

  3. Oocytes of women who are obese or overweight have lower levels of n-3 polyunsaturated fatty acids compared with oocytes of women with normal weight

    Fertility and Sterility, Vol. 113, Núm. 1, pp. 53-61

2019

  1. Acidurias orgánicas y defectos del ciclo de la urea

    Manual de pediatría (Ergon), pp. 675-680

  2. Asymmetric dimethylarginine as a potential biomarker for management and follow-up of phenylketonuria

    European Journal of Pediatrics, Vol. 178, Núm. 6, pp. 903-911

  3. Dieta en los trastornos del ciclo de la urea

    Nutrición y dietética clínica (Elsevier), pp. 387-392

  4. Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders

    Journal of pharmaceutical and biomedical analysis, Vol. 176, pp. 112798

  5. Reply-Letter to the Editor-Is liver steatosis diagnostic of non-alcoholic fatty liver disease in patients with hereditary fructose intolerance?

    Clinical Nutrition

2018

  1. Dislipemias genéticas

    Protocolos de diagnóstico y tratamiento de los errores congénitos del metabolismo (Ergon), pp. 135-154

  2. Frontoparietal subdural hematoma in a child with mental regression

    JAMA Neurology

  3. New CTSA mutation in early infantile galactosialidosis

    Pediatrics International

2017

  1. An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 13, Núm. 4, pp. 439-448

  2. Influence of phenylketonuria's diet on dimethylated arginines and methylation cycle

    Medicine (United States), Vol. 96, Núm. 27

  3. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: Patient perspectives

    Patient Preference and Adherence, Vol. 11, pp. 1489-1496

2016

  1. Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects

    Journal of Physiology and Biochemistry, Vol. 72, Núm. 3, pp. 567-582

  2. Lipid profile status and other related factors in patients with Hyperphenylalaninaemia

    Orphanet Journal of Rare Diseases, Vol. 11, Núm. 1

  3. Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis

    Journal of Hepatology, Vol. 64, Núm. 2, pp. 409-418

  4. Molecular epidemiology, genotype-phenotype correlation and BH 4 responsiveness in Spanish patients with phenylketonuria

    Journal of Human Genetics, Vol. 61, Núm. 8, pp. 731-744

  5. Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats

    Journal of Physiology and Biochemistry, Vol. 72, Núm. 3, pp. 555-566

2015

  1. 6R-tetrahydrobiopterin treated PKU patients below 4years of age: Physical outcomes, nutrition and genotype

    Molecular Genetics and Metabolism, Vol. 115, Núm. 1, pp. 10-16